• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Early initiation of antiretroviral therapy linked with lower risk of cognitive impairment in HIV

bys25qthea
January 18, 2013
in Chronic Disease, Infectious Disease, Neurology, Psychiatry, Public Health
Reading Time: 5 mins read
0
Share on FacebookShare on Twitter

Jan 18th  – Early initiation of therapy may be neuroprotective in patients recently diagnosed with HIV.

[tabs tab1=”2MM Rundown” tab2= “Full 2MM Report” tab3=”About the Authors”]

[tab]

Image: GNU2./N.Rougier. SEM of a neuron. 

1. In the era of combined antiretroviral therapy, the neurocognitive sequelae of HIV are becoming increasingly important therapeutic targets. 

2. Early initiation of therapy may be neuroprotective in patients recently diagnosed with HIV.

This study demonstrated no significant difference in the prevalence of NCI between aggressively treated HIV-infected patients and HIV-negative controls.  The study benefits from using a sample of military personnel, who receive regular HIV testing, allowing treatment to be initiated early in the course of infection.  In these patients, the regimen appears to be effective, as demonstrated by a low rate of AIDS-defining events in late-stage infection and no such events in patients with infection of a duration less than six years.  The results regarding NCI support the idea that early diagnosis and treatment may in fact lower the risk of developing HIV-associated NCI. It should be noted that the exact risk of HIV-associated NCI without early diagnosis and treatment is not known, although various studies have estimated it to be greater than what was seen in this study.

RELATED REPORTS

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

The 2 Minute Medicine Podcast Episode 6

Lecanemab may slow cognitive decline in early Alzheimer’s disease

The primary limitation of this study may be its size and cross-sectional design.  While numerous relationships observed between clinical variables and NCI neared significance, ad hoc analyses were required to demonstrate any significant associations.  Moreover, the specific protocol of ART initiation in patients was not described, making it difficult to quantify how aggressively the participants were treated.  Finally, military patients are at particular risk for neurocognitive sequelae as a result of their occupation (e.g. higher risk of traumatic brain injury), which may confound some of the comparisons.  Regardless, this study provides substantial support for the increasingly popular notion that aggressive treatment of HIV may indeed have neuroprotective benefits.

Click to read the study in Neurology

[/tab]

[tab]

Image: GNU2./N.Rougier. SEM of a neuron. 

1. In the era of combined antiretroviral therapy, the neurocognitive sequelae of HIV are becoming increasingly important therapeutic targets. 

2. Early initiation of therapy may be neuroprotective in patients recently diagnosed with HIV.

Primer: Human immunodeficiency virus (HIV) infection represents a significant global health burden, with the most recent prevalence estimates nearing 34 million worldwide.  Though a particular problem of sub-Saharan Africa, HIV affects a large number of patients in developed countries including the United States.  Treatment is supportive, and the development of highly effective antiretroviral drug regimens in recent years has greatly extended the lifespan of patients with HIV.  Although there is some debate as to the proper time of treatment initiation, antiretroviral therapy (ART) has proven to be tremendously efficacious in combating the disease and raising CD4+ cell counts in patients with confirmed HIV infection.

As patients with HIV are living longer with ART, the neurologic complications of infection are being increasingly recognized.  HIV has long been known to have a predilection for the central nervous system.  Moreover, drug delivery to the brain is challenging due to the highly regulated transport systems of the blood-brain barrier.  While the pathophysiology of so-called “neuro-HIV” is not yet fully understood, the consequences of CNS infection are well described, most notably the syndrome of neurocognitive impairment (NCI), which often develops in patients with long-standing and/or severe infection.  The literature describing the clinical predictors of NCI in HIV infection is inconclusive, though it is generally assumed that early control of infection is an important protective strategy.  In the present study, the authors investigate the presence of NCI in HIV positive patients with varying durations of infection who were all started on ART early in their disease course in order to examine the role of aggressive treatment in preventing NCI.

Background reading:

  1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.
  2. Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion.
  3. HIV-1 infection and cognitive impairment in the cART era: a review

This [cross-sectional] study: 200 HIV-infected and 50 HIV-negative military personnel participated, the former stratified into early-stage disease (<6 years since diagnosis, no history of AIDS-defining conditions, and nadir CD4 >200 cells/mm3; n=100) and late-stage disease (violating any of the aforementioned criteria; n=100). Neurocognitive impairment was present in 19% of HIV-infected patients, with no significant difference between early- and late-stage disease.  Of HIV-negative controls, 30% demonstrated NCI, which was not significantly different from the proportion of HIV-infected participants.  Plasma viral load, nadir CD4, and treatment variables were not associated with the presence of NCI.

In sum: This study demonstrated no significant difference in the prevalence of NCI between aggressively treated HIV-infected patients and HIV-negative controls.  The study benefits from using a sample of military personnel, who receive regular HIV testing, allowing treatment to be initiated early in the course of infection.  In these patients, the regimen appears to be effective, as demonstrated by a low rate of AIDS-defining events in late-stage infection and no such events in patients with infection of a duration less than six years.  The results regarding NCI support the idea that early diagnosis and treatment may in fact lower the risk of developing HIV-associated NCI. It should be noted that the exact risk of HIV-associated NCI without early diagnosis and treatment is not known, although various studies have estimated it to be greater than what was seen in this study.

The primary limitation of this study may be its size and cross-sectional design.  While numerous relationships observed between clinical variables and NCI neared significance, ad hoc analyses were required to demonstrate any significant associations.  Moreover, the specific protocol of ART initiation in patients was not described, making it difficult to quantify how aggressively the participants were treated.  Finally, military patients are at particular risk for neurocognitive sequelae as a result of their occupation (e.g. higher risk of traumatic brain injury), which may confound some of the comparisons.  Regardless, this study provides substantial support for the increasingly popular notion that aggressive treatment of HIV may indeed have neuroprotective benefits.

Click to read the study in Neurology 

By [JD] and [RR]

More from this author: The virtual lumbar puncture: MRI can predict CSF biomarker levels in patients with neurodegenerative disease, Intracranial pressure monitoring does not increase survival in patients with traumatic brain injury, PET imaging findings may precede cognitive impairment in patients at high risk for Alzheimer’s disease,Initial dexamethasone improves long-term survival in acute bacterial meningitis

[/tab]

[tab]

Rif Rahman: Rif is a 4th year M.D. candidate at Harvard Medical School.

 

 

 

 

Jeff Dewey: Jeff Dewey is a 4th year M.D. candidate at the Boston University School of Medicine.

 

 

 

 

[/tab]

[/tabs]

 

Tags: ARTHIVNCIneuro HIVneurology
Previous Post

[Physician Comment] Early antiretroviral therapy in HIV linked with increased likelihood of CD4+ recovery

Next Post

Pediatric providers who completed tobacco education program more likely to educate parental smokers about quitting

RelatedReports

Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

January 27, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 6

January 13, 2023
Free alternatives comparable to Mini-Mental State Examination
Chronic Disease

Lecanemab may slow cognitive decline in early Alzheimer’s disease

January 10, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

January 11, 2023
Next Post

Pediatric providers who completed tobacco education program more likely to educate parental smokers about quitting

Influenza infection during pregnancy associated with increased risk of fetal death

Young women now more likely to contract genital Herpes Simplex 1 (HSV-1) than HSV-2

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options